Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease by William Connors et al.
Connors et al. BMC Gastroenterology 2014, 14:127
http://www.biomedcentral.com/1471-230X/14/127CASE REPORT Open AccessLymphomatoid granulomatosis associated with
azathioprine therapy in Crohn disease
William Connors1†, Cameron Griffiths1†, Jay Patel2† and Paul J Belletrutti3*Abstract
Background: Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus-associated lymphoproliferative
disorder. It most often occurs in patients with immunodeficiency and the clinical course ranges from indolent
behavior to that of an aggressive malignancy. Pulmonary, central nervous system and dermatological manifestations
are most common. To our knowledge this is the first reported case of LYG related to azathioprine therapy in Crohn
disease.
Case presentation: A twenty-six year old Caucasian woman with colonic Crohn disease on maintenance azathioprine
therapy presented with right upper quadrant pain and fever. Diagnostic imaging revealed extensive liver, pulmonary
and cerebral lesions. A diagnosis of LYG was made based on the pattern of organ involvement and the
immunohistochemical features on liver and lung biopsy.
Conclusions: Thiopurine therapy for inflammatory bowel disease is associated with an increased incidence of
lymphoproliferative disorders. This report highlights the diagnostic challenges associated with LYG. As long-term
thiopurine therapy remains central to the management of inflammatory bowel diseases it is essential that both
patients and clinicians are aware of this potential adverse outcome.
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Lymphomatoid granulomatosis (LYG), first described by
Liebow et al. in 1972 [1], is a rare Epstein-Barr Virus
(EBV)-associated lymphoproliferative disorder. LYG is
classically described as primarily extranodal in nature in-
volving the lungs, skin, central nervous system and liver.
It is an incompletely understood clinical entity with a
median survival of 14 months from the time of diagnosis.
Age at first presentation is typically between the fourth
and sixth decade with a male to female ratio of two to
one. Although it may occur in immunocompetent hosts,
there is a strong association with immune deficiency, both
humoral and cell mediated. Clinical presentation is often
non-specific with pulmonary involvement being most
common and manifesting as cough, shortness of breath or
chest pain [1-4].* Correspondence: pjbellet@ucalgary.ca
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unless otherwise stated.Histopathologically, LYG is characterized as a mixed
mononuclear cell infiltrate with atypical large CD20+
B-lymphocytes on the background of reactive CD3+
T- lymphocytes, histiocytes and plasma cells. The infil-
trate is angiocentric and typically invades the microvascu-
lature. It is graded from I to III based on both the number
of large B-cells and the proportion that stain positively for
EBV-encoded small RNA (EBER) by in situ hybridization
(ISH) [2]. The presence of these EBER-positive large B-cells
and vascular invasion are keys to the diagnosis of LYG.
Grade I and II LYG are slowly progressive while grade III
LYG is aggressive with poor prognosis and requires treat-
ment with multi-agent immunochemotherapy.
Here we present a case of LYG in a 26-year-old Caucasian
female receiving azathioprine maintenance therapy for
Crohn disease (CD) who presented with primary gastro-
intestinal complaints and fever. This report will high-
light the diagnostic challenges associated with LYG and
describe what we believe to be the first documented
case of this rare disease in the setting of azathioprine
treatment for CD.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Diagnostic imaging features of lymphomatoid
granulomatosis in our case. A) T2 weighted axial magnetic
resonance (MR) image showing hyperintense lesions in the
liver. B) CT axial image showing irregular bilateral pulmonary
opacities with peripheral predominance and areas of ground-glass
changes classic for lymphomatoid granulomatosis.
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A 26-year-old Caucasian woman presented with three days
of right upper quadrant pain, fever, and malaise. She had a
six-year history of Crohn colitis initially treated with high
dose mesalamine (4 g daily) then transitioned to azathio-
prine (2.5 mg/kg) after loss of response. She had been
in clinical remission on azathioprine for the preceding
14 months. The patient had not been on any other im-
mune modulating or biologic therapies.
Physical examination revealed focal right upper quadrant
abdominal tenderness but no palpable masses, organome-
galy or signs of ascites. Laboratory review revealed new
onset pancytopenia (hemoglobin = 119 g/L, neutrophils =
1.4 × 109/L, platelets = 80 x109/L), cholestatic liver enzyme
elevation (GGT= 272 U/L, ALP = 342 U/L) and hepatic
synthetic impairment (bilirubin = 19 umol/L, INR = 1.8,
albumin = 24 g/L). Azathioprine therapy was suspended.
Investigations failed to identify a source of infection;
however, magnetic resonance (MR) imaging revealed
hepatomegaly with periportal, gastrohepatic, and retro-
peritoneal lymphadenopathy. A clinical diagnosis of
azathioprine-associated pancytopenia with a concur-
rent non-A-E viral hepatitis was favored. She was ad-
ministered G-CSF and transitioned to oral antibiotics.
After clinical improvement, the patient was discharged
from hospital with planned repeat MR imaging in one
to two months.
Six weeks later, she developed progressive abdominal
pain, night sweats, and non-positional presyncopal symp-
toms. The patient did not report diarrhea or GI bleeding.
Endoscopic evaluation of the upper GI tract and colon
were normal with no evidence of inflammation or active
Crohn disease. She had also developed her first outbreak
of genital herpes (serologically HSV-2) for which she was
started on antiviral therapy. Repeat MR imaging now
demonstrated extensive T2 hyperintense lesions distributed
throughout her liver and both kidneys (Figure 1A).
Over the next weeks in hospital, she experienced pro-
gressive abdominal bloating, malaise, dyspnea and night
sweats without documented fevers. Computed tomog-
raphy (CT) of her lungs revealed extensive, peripherally
distributed, bilateral ground-glass opacifications (Figure 1B).
Bronchoalveolar lavage and transbronchial biopsy were
negative for infection or malignancy. A comprehensive in-
fectious diseases work-up was negative; of note serology
and PCR viral titers for EBV were negative. HIV serology
was negative. Core biopsy of the liver revealed atypical B-
lymphocyte proliferation with prominent angiocentricity
(Figure 2A). The EBV encoded small RNA (EBER) stain-
ing by in situ hybridization was negative (Figure 2B). Thus
the liver biopsy was classified by hematopathologist
consensus as an “atypical lymphoid infiltrate”. Further
work-up with a bone marrow biopsy showed no morpho-
logic abnormalities and was EBER-negative. An MR of thehead revealed multiple cerebellar, cortical and subcortical
enhancing lesions (Figure 3). As the lesions appeared to
be infarcts of different ages across different territories, a
vasculitic process was suggested but a subsequent sero-
logical work-up was negative.
The patient opted to leave hospital pending consultation
opinions on her liver biopsy and one month later returned
to hospital with worsening dyspnea, cough and fevers. She
underwent video-assisted thoracoscopic surgery (VATS)
during which a wedge biopsy of her lung was obtained. In
the days prior to surgery she had developed right pleural
effusion and lower lobe pneumonia. Cultures from her
pleural fluid grew Streptococcus milleri and Prevotella
species, therefore she received a six-week course of paren-
teral antibiotics.
Now four months after her initial presentation, the
VATS-acquired lung wedge biopsy demonstrated EBER
positivity in an atypical CD20+ lymphocyte infiltrate
with vascular invasion sufficient to confirm a diagnosis
of grade II LYG (Figure 2C, D). Expert pathology opin-
ion from the National Institutes of Health (Bethesda,
MD) concurred with the diagnosis. Over this period
the patient had several transient episodes of left lower
Figure 2 Histopathology features of lymphomatoid granulomatosis in our case. A) H&E stain of liver core biopsy with a periportal
polymorphous infiltrate composed of small lymphocytes, histiocytes, and plasma cells. B) EBV in situ hybridization (EBER) of liver showing no
positively stained cells. C) H&E stain of lung wedge biopsy showing an extensive, focally angiocentric, polymorphic infiltrate with geographic
tissue necrosis. D) EBER of lung showing scattered positive nuclear staining in the distribution of B-cells (CD20 immunostain not shown).
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vealed interval development of new enhancing lesions
in both cerebral hemispheres with mild surrounding
edema and small internal foci of microhemorrhage.
Treatment was initiated with subcutaneous recombinant
interferon-alpha three times weekly titrated up to 10 million
units per m2 of body surface area and four weekly
doses of rituximab 375 mg/m2. Her treatment courseFigure 3 Central nervous system lesion in our case. T2 weighted MR im
cortex and B) right cerebellar cortex.was complicated by neutropenia requiring granulocyte
colony stimulating factor (G-CSF), choledocholithiasis
requiring cholecystectomy and admission to hospital with
recurrent pneumonia. With therapy, all of her systemic
lesions have steadily improved. This patient is alive and
tolerating ongoing therapy at 12 months follow-up.
Our patient is the first reported case we are aware of
with LYG in the context of CD and azathioprine use.age showing a large hyperintense lesion in A) right frontal cerebral
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age, female gender, and the predominance of hepatic in-
volvement preceding other pulmonary and CNS manifes-
tations. In the larger context of LYG, only three percent of
cases present with gastrointestinal symptoms; the majority
primarily manifest pulmonary symptoms [1-4].
In our case, the diagnosis of LYG was suspected based
on pattern recognition on lung imaging and suggestive
liver pathology. The negative EBV staining and lack of
necrosis on the liver biopsy sample pointed away from
LYG as the diagnosis. After open lung biopsy, however,
the classic features of LYG were revealed, namely atypical
large B-cells that were EBER-positive, vascular invasion
and necrosis. These pathological findings along with
the patient’s clinical presentation and pattern of organ
involvement clinched the diagnosis of LYG. This case
highlights the difficulty of establishing the diagnosis of
LYG in many cases due to sampling error and histo-
logical heterogeneity in a given patient depending on
the site biopsied [5].
The current literature on LYG in association with CD
or azathioprine is limited to two case reports. The first
was a 17-year-old female patient with CD who developed
LYG (stage III) with nasopharyngeal and pulmonary
predominance following six years of 6-mercaptopurine
therapy. She received systemic immunochemotherapy
and was in clinical remission at four years follow-up
[6]. The second was a 69-year-old female who developed
LYG (stage III) with central nervous system predominance
following ten months of azathioprine therapy for auto-
immune hepatitis. Despite initiation of systemic therapy
the patient died 34 days after diagnosis due to sepsis and
cardio-pulmonary failure [7]. From these two case reports
an independent association between the two major fea-
tures of our case -CD and azathioprine (a thiopurine
pro-drug of 6-mercaptopurine)– with the development
of LYG can be theorized.
Multiple population-based studies of inflammatory
bowel diseases (IBD) have not shown an excess risk of
lymphoproliferative disorders (LD) over baseline in part
because it is difficult to rule out an effect from the disease
itself in the population of patients who require more in-
tensive therapy [8,9]. However, studies evaluating the risk
of LD in the setting of CD and thiopurine therapy,
summarized in a review by Beaugerie et al [9], support
an approximate five-fold therapy specific elevated risk.
Along with other smaller retrospective cohort analyses,
the CESAME study, a nationwide French prospective
observational cohort study of 19,486 patients with IBD,
showed an independent association between ongoing
thiopurine therapy for IBD and the risk of LD (multi-
variate-adjusted hazard ratio = 5.28, CI 2.01-13.9, p =
0.0007) [10-12]. It should be noted that the CESAME
Study Group concluded the absolute cumulative risk ofLD after ten years of thiopurines was less than one per-
cent. This cohort had no patients diagnosed with LYG.
Consistent with the findings in our patient, a compre-
hensive review of all LYG case series by Katzenstein et al.
[4] illustrates the central role of underlying primary or
secondary immunodeficiency leading to EBV reactivation.
This may result in viral binding of lymphocyte membrane
proteins and subsequent viral genome insertion facilitating
oncogenesis [4]. Iatrogenic T-cell immunosuppression
secondary to thiopurines is consistent with this proposed
pathogenesis and was likely the predisposing factor in our
case. Crohn disease-related lymphomas have been shown
to have a higher prevalence of EBV-related subtypes, and
in some EBV-related lymphoproliferative disorders disease
remission has been seen with withdrawal of immunosup-
pression [13].
Conclusions
Here we present the first case in the literature of lym-
phomatoid granulomatosis in the setting of azathio-
prine therapy for Crohn disease. LYG is one of several
EBV-driven conditions that should be considered when
a lymphoproliferative disorder develops in an immuno-
compromised patient.
The atypical features in our case underscore the import-
ance of maintaining a high degree of clinical suspicion and
diagnostic vigilance when evaluating non-specific abdom-
inal symptoms frequently encountered in CD patients. This
case highlights that even limited exposure to such therapy
may induce LYG. Future research is needed into the
pathogenesis and early detection of this disease to allow
both clinicians and patients to make informed decisions
and to raise awareness of this uncommon disorder.
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